Antoine Bonnet

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

Emmanuelle Tchernonog, P. Faurie, Paul Coppo et al. · Annals of Oncology · 2016 · 124 citations

Hematological Malignancy, Lymphoid Neoplasia, Health Sciences +11

BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment

Patricia Gomez‐Bougie, Sophie Maïga, Benoît Tessoulin et al. · Blood · 2018 · 74 citations · Full text

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Maxime Jullien, Sabrina Trudel, Benoît Tessoulin et al. · Annals of Hematology · 2019 · 33 citations

Hematological Malignancy, Single-agent Daratumumab, Medicine +4

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 ⁺ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Patrice Chevallier, Thibaut Leguay, Marc Delord et al. · Journal of Clinical Oncology · 2024 · 30 citations

Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma

Anne Lok, J. Mocquard, Jessie Bourcier et al. · Haematologica · 2014 · 17 citations · Full text

Hematological Malignancy, Cell Therapy, Transplantation +15